EGFR and non-small cell lung carcinoma: A Japanese randomized controlled study included 102 patients with EGFR-mutant NSCLC after TKIs resistance, with a mPFS of 1.7 months in the nivolumab group and 5.6 months in the carboplatin-pemetrexed group and differences were significant (21).